Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by XTX Topco Ltd

XTX Topco Ltd decreased its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 66.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,210 shares of the company’s stock after selling 42,870 shares during the quarter. XTX Topco Ltd’s holdings in Myriad Genetics were worth $188,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Northern Trust Corp boosted its holdings in Myriad Genetics by 6.7% in the fourth quarter. Northern Trust Corp now owns 1,032,132 shares of the company’s stock worth $14,151,000 after purchasing an additional 64,923 shares during the period. Barclays PLC boosted its holdings in shares of Myriad Genetics by 7.3% in the 4th quarter. Barclays PLC now owns 204,051 shares of the company’s stock valued at $2,797,000 after buying an additional 13,808 shares during the period. Blue Trust Inc. grew its position in shares of Myriad Genetics by 57.0% during the 1st quarter. Blue Trust Inc. now owns 14,367 shares of the company’s stock valued at $127,000 after buying an additional 5,214 shares during the last quarter. Man Group plc acquired a new stake in Myriad Genetics during the fourth quarter worth about $390,000. Finally, Invesco Ltd. raised its stake in Myriad Genetics by 37.9% during the fourth quarter. Invesco Ltd. now owns 769,284 shares of the company’s stock worth $10,547,000 after acquiring an additional 211,503 shares during the period. 99.02% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MYGN has been the subject of several recent research reports. Craig Hallum set a $18.00 target price on Myriad Genetics and gave the company a “buy” rating in a report on Wednesday, May 7th. The Goldman Sachs Group reduced their price objective on Myriad Genetics from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Raymond James Financial reaffirmed an “outperform” rating and issued a $10.00 target price (down from $19.00) on shares of Myriad Genetics in a research report on Wednesday, May 7th. Piper Sandler reduced their price target on shares of Myriad Genetics from $12.50 to $9.00 and set an “overweight” rating for the company in a report on Thursday, May 15th. Finally, UBS Group lowered their price target on shares of Myriad Genetics from $16.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.45.

Myriad Genetics Trading Down 2.7%

Myriad Genetics stock opened at $5.87 on Thursday. Myriad Genetics, Inc. has a 52 week low of $3.76 and a 52 week high of $29.30. The stock has a market cap of $546.14 million, a price-to-earnings ratio of -1.37 and a beta of 1.89. The company’s 50-day moving average price is $5.06 and its two-hundred day moving average price is $7.55.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.